Elizabeth Smith's Title: Scaling the Impact of PSMA-PET in Clinical Decision Making
ABSTRACT: Prostate cancer is the most common cancer and third-leading cause of cancer death for men in the United States. In December 2020, the FDA granted approval to UCSF and UCLA for the use of 68Ga-PSMA-11, a positron emission tomography (PET) radiotracer that specifically labels prostate cancer cells, based on clinical trials that demonstrated improved sensitivity for detecting cancerous lesions compared with the current standard of care. Elizabeth will present progress towards building an Artificial Intelligence-based tool to standardize interpretation and minimize interobserver variability of 68Ga-PSMA-11 PET reconstructions.
Reza Eghbali's Title: A Treatment Recommendation System for CNS Lymphoma
ABSTRACT: CNS lymphoma is a non-systematic variant of lymphoma that involves the central nervous system. There are multiple treatment options for CNS lymphoma and substantial variation of treatment choice in clinical practice. Our goal is to develop a system for assessing each treatment based on imaging and clinical biomarkers that can assist physicians in choosing the best treatment for the patient with an eye towards the development of tools that can be useful for other neurological conditions. These tools include a system for longitudinal MRI analysis of brain tumors which is also of value for many other conditions such as low-grade glioma, glioblastoma, etc. In this talk, we present our preliminary results based on the analysis of the data extracted from the medical records and MR imaging of CNS lymphoma patients.